Show simple item record

dc.contributor.authorGiles, SL
dc.contributor.authorMessiou, C
dc.contributor.authorCollins, DJ
dc.contributor.authorMorgan, VA
dc.contributor.authorSimpkin, CJ
dc.contributor.authorWest, S
dc.contributor.authorDavies, FE
dc.contributor.authorMorgan, GJ
dc.contributor.authordeSouza, NM
dc.date.accessioned2017-01-03T14:10:46Z
dc.date.issued2014-06
dc.identifier.citationRadiology, 2014, 271 (3), pp. 785 - 794
dc.identifier.issn0033-8419
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/358
dc.identifier.eissn1527-1315
dc.identifier.doi10.1148/radiol.13131529
dc.description.abstractPurpose To determine the feasibility of whole-body diffusion-weighted (DW) magnetic resonance (MR) imaging for assessment of treatment response in myeloma.Materials and methods This prospective single-institution study was HIPAA-compliant with local research ethics committee approval. Written informed consent was obtained from each subject. Eight healthy volunteers (cohort 1a) and seven myeloma patients (cohort 1b) were imaged twice to assess repeatability of quantitative apparent diffusion coefficient (ADC) estimates. Thirty-four additional myeloma patients (cohort 2) underwent whole-body DW imaging before treatment; 26 completed a posttreatment imaging. Whole-body DW data were compared before and after treatment by using qualitative (ie, observer scores) and quantitative (ie, whole-body segmentation of marrow ADC) methods. Serum paraproteins and/or light chains or bone marrow biopsy defined response.Results Whole-body DW imaging scores were significantly different between observers (P < .001), but change in scores between observers after treatment was not (P = .49). Sensitivity and specificity for detecting response according to observer scores were 86% (18 of 21 patients) and 80% (4 of 5 patients) for both observers. ADC measurement was repeatable: mean coefficient of variation was 3.8% in healthy volunteers and 2.8% in myeloma patients. Pretreatment ADC in cohort 2 was significantly different from that in cohort 1a (P = .03), but not from that in cohort 1b (P = .2). Mean ADC increased in 95% (19 of 20) of responding patients and decreased in all (five of five) nonresponders (P = .002). A 3.3% increase in ADC helped identify response with 90% sensitivity and 100% specificity; an 8% increase (greater than repeatability of cohort 1b) resulted in 70% sensitivity and 100% specificity. There was a significant negative correlation between change in ADC and change in laboratory markers of response (r = -0.614; P = .001).Conclusion Preliminary work demonstrates whole-body DW imaging is a repeatable, quantifiable technique for assessment of treatment response in myeloma.
dc.formatPrint-Electronic
dc.format.extent785 - 794
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectMultiple Myeloma
dc.subjectBoronic Acids
dc.subjectThalidomide
dc.subjectCyclophosphamide
dc.subjectPyrazines
dc.subjectDexamethasone
dc.subjectGranulocyte Colony-Stimulating Factor
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDiffusion Magnetic Resonance Imaging
dc.subjectTreatment Outcome
dc.subjectProspective Studies
dc.subjectPilot Projects
dc.subjectReproducibility of Results
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectWhole Body Imaging
dc.subjectBortezomib
dc.subjectLenalidomide
dc.titleWhole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
dc.typeJournal Article
rioxxterms.versionofrecord10.1148/radiol.13131529
rioxxterms.licenseref.startdate2014-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfRadiology
pubs.issue3
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Myeloma Target Treatment
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Myeloma Target Treatment
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.publication-statusPublished
pubs.volume271
pubs.embargo.termsNot known
icr.researchteamMyeloma Target Treatmenten_US
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
icr.researchteamMagnetic Resonanceen_US
dc.contributor.icrauthorMorgan, Gareth Johnen
dc.contributor.icrauthorDavies, Faith Elizabethen
dc.contributor.icrauthordeSouza, Nanditaen
dc.contributor.icrauthorGiles, Sharonen
dc.contributor.icrauthorMessiou, Christinaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record